In clinical trials, serum MMP-9 levels were markedly higher in patients with COPD than in the non-smoker control group, and an increase in MMP-9 was associated with a decrease in FEV1% [48]. This evidence concerns the gene MMP9 and chronic obstructive pulmonary disease.